Creative Medical Technology Holdings, Inc. financial data

Symbol
CELZ on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
211 E. Osborn Rd., Phoenix, AZ
State of incorporation
NV
Fiscal year end
December 31
Former names
JOLLEY MARKETING INC (to 5/13/2016)
Latest financial report
10-K - Q4 2024 - Mar 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.05K % -35.5%
Quick Ratio 1.09 % -49.6%
Debt-to-equity 4.79 % +52.9%
Return On Assets -70.5 % -75.3%
Operating Margin -52.2K % +16.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.75M shares +28.9%
Common Stock, Shares, Outstanding 1.75M shares +27.3%
Entity Public Float 5.15M USD -22.3%
Common Stock, Value, Issued 1.75K USD +22.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 11K USD +22.2%
Cost of Revenue 4.4K USD +22.2%
Research and Development Expense 2.4M USD +21.8%
Operating Income (Loss) -5.74M USD -2.2%
Nonoperating Income (Expense) 250K USD -24.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.49M USD -3.91%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -5.49M USD -3.91%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.51M USD
Inventory, Net 2.19K USD -66.7%
Assets, Current 6.14M USD -40.3%
Assets 6.67M USD -37.8%
Accounts Payable, Current 274K USD -13.8%
Accrued Liabilities, Current 39.9K USD 0%
Liabilities, Current 328K USD -11.8%
Liabilities 328K USD -11.8%
Retained Earnings (Accumulated Deficit) -64.6M USD -9.3%
Stockholders' Equity Attributable to Parent 6.34M USD -38.7%
Liabilities and Equity 6.67M USD -37.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -897K USD +76.7%
Net Cash Provided by (Used in) Financing Activities -82.8K USD
Net Cash Provided by (Used in) Investing Activities 6.52M USD +29.4%
Common Stock, Shares Authorized 25M shares +400%
Common Stock, Shares, Issued 1.75M shares +22.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.94M USD +71.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 7.66M USD +22.3%
Deferred Tax Assets, Operating Loss Carryforwards 7.66M USD +22.3%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 70.9M USD +1.75%
Amortization of Intangible Assets 110K USD +16.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 9.16K USD 0%
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%